Top Stories

Jun, 2020

Esperion has announced that NEXLIZET™ (bempedoic acid and ezetimibe) Is now available in pharmacies in the United States. NEXLIZET™ is an oral, once-daily, fixed-dose combination tablet indicated as an adjunct to diet and maximally tolerated statin for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.

 

0
No votes yet
Mar, 2020

Esperion has announced that NEXLETOL™ (bempedoic acid) is now available in pharmacies in the United States. NEXLETOL is an oral, once-daily, tablet indicated as an adjunct to diet and maximally tolerated statin for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.

0
No votes yet
May, 2019

An encore presentation of the landmark cardiovascular outcomes trial REDUCE-IT™ (Reduction of Cardiovascular Events With EPA - Intervention Trial) was presented as a Late-Breaking Abstract by Amarin at the National Lipid Association 2019 Scientific Sessions, taking place in Miami May 16 – 19.

The presentation on Saturday, May 18, 4:40-4:50 p.m. included the total events analysis from the REDUCE-IT study, as first presented March 2019 and published in the Journal of the American College of Cardiology.

0
No votes yet